个人中心 - 老虎社区

Riyasaan

IP属地：未知

帖子 · 62帖子 · 62
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- RiyasaanRiyasaan
  ·2021-07-21
  Good
  非常抱歉，此主贴已删除
  1,866 3
  4
  分享
  举报
- RiyasaanRiyasaan
  ·2021-07-01
  Good
  The S&P 500 Notches Its Second-Best First Half Since the Dot-Com Bubble. What Comes Next.<blockquote>标普500取得了自互联网泡沫以来第二好的上半年成绩。接下来会发生什么。</blockquote>
  Since 1979, the S&P 500 has gained 10% or more 14 times during the first half of the year. The S&P 5
  The S&P 500 Notches Its Second-Best First Half Since the Dot-Com Bubble. What Comes Next.<blockquote>标普500取得了自互联网泡沫以来第二好的上半年成绩。接下来会发生什么。</blockquote>
  1,536 评论
  5
  分享
  举报
- RiyasaanRiyasaan
  ·2021-06-30
  Great
  Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>
  The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to
  Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>
  2,637 评论
  点赞
  分享
  举报
- RiyasaanRiyasaan
  ·2021-06-22
  $Salesforce.com(CRM)$Holding.
  1,551 1
  4
  分享
  举报
- RiyasaanRiyasaan
  ·2021-06-19
  $TAL Education Group(TAL)$Pls go up
  1,360 评论
  3
  分享
  举报
- RiyasaanRiyasaan
  ·2021-06-18
  Ok
  非常抱歉，此主贴已删除
  1,928 评论
  1
  分享
  举报
- RiyasaanRiyasaan
  ·2021-06-18
  Good
  非常抱歉，此主贴已删除
  1,519 评论
  1
  分享
  举报
- RiyasaanRiyasaan
  ·2021-06-18
  $Salesforce.com(CRM)$Keeping strong
  1,173 2
  2
  分享
  举报
- RiyasaanRiyasaan
  ·2021-06-16
  $Salesforce.com(CRM)$Strong
  1,642 1
  点赞
  分享
  举报
- RiyasaanRiyasaan
  ·2021-06-16
  $TAL Education Group(TAL)$can we expect10% up move from here
  1,418 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3576125105535390","uuid":"3576125105535390","gmtCreate":1613039786311,"gmtModify":1617685868459,"name":"Riyasaan","pinyin":"riyasaan","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/853ccf8f0efed6f3b600123ec0b321c3","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":14,"headSize":98,"tweetSize":62,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.63%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.70%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":176958519,"gmtCreate":1626856466131,"gmtModify":1631890700048,"author":{"id":"3576125105535390","authorId":"3576125105535390","name":"Riyasaan","avatar":"https://static.tigerbbs.com/853ccf8f0efed6f3b600123ec0b321c3","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576125105535390","idStr":"3576125105535390"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/176958519","repostId":"1179602567","repostType":4,"isVote":1,"tweetType":1,"viewCount":1866,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158925597,"gmtCreate":1625124967619,"gmtModify":1631890700053,"author":{"id":"3576125105535390","authorId":"3576125105535390","name":"Riyasaan","avatar":"https://static.tigerbbs.com/853ccf8f0efed6f3b600123ec0b321c3","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576125105535390","idStr":"3576125105535390"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158925597","repostId":"1106223449","repostType":4,"repost":{"id":"1106223449","kind":"news","pubTimestamp":1625122086,"share":"https://www.laohu8.com/m/news/1106223449?lang=zh_CN&edition=full","pubTime":"2021-07-01 14:48","market":"us","language":"en","title":"The S&P 500 Notches Its Second-Best First Half Since the Dot-Com Bubble. What Comes Next.<blockquote>标普500取得了自互联网泡沫以来第二好的上半年成绩。接下来会发生什么。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1106223449","media":"Barrons","summary":"Since 1979, the S&P 500 has gained 10% or more 14 times during the first half of the year.\nThe S&P 5","content":"<p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d70d0323609e9ce596a9a90e475422d1\" tg-width=\"1260\" tg-height=\"840\"><span>Since 1979, the S&amp;P 500 has gained 10% or more 14 times during the first half of the year.</span></p><p><blockquote><p class=\"t-img-caption\"><span>自1979年以来，标普500上半年涨幅达到或超过10%已有14次。</span></p></blockquote></p><p> The S&amp;P 500 closed its second-best first half since the dot-com bubble. Don’t be surprised if the stock market keeps on rising.</p><p><blockquote>标普500的上半年表现是自互联网泡沫以来第二好的。如果股市继续上涨，不要感到惊讶。</blockquote></p><p> With June coming to an end, the S&amp;P 500 finished the first half of 2021 with a gain of 14.4%. Since 1998, only 2019’s 17.4% first-half surge has been larger.</p><p><blockquote>随着6月接近尾声，标普500以14.4%的涨幅结束了2021年上半年。自1998年以来，只有2019年上半年17.4%的增幅更大。</blockquote></p><p> The market got a boost from Covid-19 vaccinations, which have helped the U.S. economy reopen, while trillions of dollars of fiscal stimulus have helped shore up demand. The gains continued even as concerns about inflation have increased speculation that the Federal Reserve would be forced to take steps to slow the economy.</p><p><blockquote>Covid-19疫苗接种提振了市场，帮助美国经济重新开放，而数万亿美元的财政刺激措施帮助支撑了需求。尽管对通胀的担忧加剧了人们对美联储将被迫采取措施减缓经济增长的猜测，但涨幅仍在继续。</blockquote></p><p> The combination of big gains and a more hawkish Fed have raised concerns that the market has become too complacent. If inflation continues to run hot for long enough, the central bank could be forced to act more quickly than the market expects—and&nbsp;cause stocks to tumble. Others worry that&nbsp;U.S. economic growth could slow faster than investors anticipate, causing a pullback in the process.</p><p><blockquote>大幅上涨和美联储更加鹰派的结合引发了市场过于自满的担忧。如果通胀持续持续足够长的时间，央行可能会被迫以比市场预期更快的速度采取行动，并导致股市暴跌。其他人担心美国。经济增长放缓的速度可能快于投资者的预期，导致经济增长放缓。</blockquote></p><p> For those who take that view, there is no better time to back away from the stock market than the present. History suggests otherwise.</p><p><blockquote>对于持这种观点的人来说，没有比现在更好的退出股市的时机了。历史表明并非如此。</blockquote></p><p> Since 1979, the S&amp;P 500 has gained 10% or more 14 times during the first half of the year, and the index has gone on to average a 6.3% gain over the second half of the year. What’s more, the index finished the second half of the year higher In 11 of those instances, or 79% of the time.</p><p><blockquote>自1979年以来，标普500上半年涨幅达到或超过10%的有14次，下半年该指数平均涨幅为6.3%。更重要的是，该指数在下半年有11次（即79%的时间）走高。</blockquote></p><p> Even the losses, when they occurred, weren’t all that bad. The S&amp;P 500 dropped 1.9% in the second half of 1983 and 3.5% during the last six months of 1986.</p><p><blockquote>即使是损失，当它们发生时，也没有那么糟糕。标普500在1983年下半年下降了1.9%，在1986年最后六个月下降了3.5%。</blockquote></p><p> The one exception was the last six months of 1987 when the index fell 19% during the second half of the year. That period included Black Monday, when the S&amp;P 500 dropped 20% in one day, still a record loss. While selling linked to so-called&nbsp;portfolio insurance&nbsp;was ultimately blamed for the size and speed of the loss, the second half of 1987 was&nbsp;a period of rising bond yields and high stock-market valuations, just like the first half of 2021.</p><p><blockquote>一个例外是1987年的最后六个月，该指数在下半年下跌了19%。那段时间包括黑色星期一，当时标普500在一天内下跌了20%，仍然是创纪录的跌幅。虽然与所谓投资组合保险相关的抛售最终被归咎于损失的规模和速度，但1987年下半年是债券收益率上升和股市估值高的时期，就像2021年上半年一样。</blockquote></p><p> Still, the market has been acting like it wants to go higher, not lower. Pullbacks, a normal event in the midst of bull runs, have been mild in 2021, with the largest drops being less than 4%. “What the [S&amp;P 500] has done throughout 2021 is pick itself up when and where it has needed to, maintaining an uptrend all along,” writes Frank&nbsp;Cappelleri, chief market technician at Instinet.</p><p><blockquote>尽管如此，市场一直表现得想要走高，而不是走低。回调是牛市中的正常事件，在2021年表现温和，最大跌幅不到4%。Instinet首席市场技术员Frank Cappelleri写道：“[标普500]在2021年所做的就是在需要的时间和地点回升，始终保持上升趋势。”</blockquote></p><p> That 6.3% average second-half rise would push the S&amp;P 500’s full-year gain to around 23%. That would represent a “textbook [market] recovery” from a recession, says Fundstrat’s Tom Lee.</p><p><blockquote>下半年6.3%的平均涨幅将使标普500的全年涨幅达到23%左右。Fundstrat的汤姆·李(Tom Lee)表示，这将代表着从衰退中“教科书式的[市场]复苏”。</blockquote></p><p> For now, at least, the path of least resistance is higher.</p><p><blockquote>至少就目前而言，阻力最小的路径更高。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/3cb229b2e05d59b9c126d464a7d771bb\" tg-width=\"958\" tg-height=\"647\"></p><p><blockquote></blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The S&P 500 Notches Its Second-Best First Half Since the Dot-Com Bubble. What Comes Next.<blockquote>标普500取得了自互联网泡沫以来第二好的上半年成绩。接下来会发生什么。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe S&P 500 Notches Its Second-Best First Half Since the Dot-Com Bubble. What Comes Next.<blockquote>标普500取得了自互联网泡沫以来第二好的上半年成绩。接下来会发生什么。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-07-01 14:48</span>\n</p>\n</h4>\n</header>\n<article>\n<p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d70d0323609e9ce596a9a90e475422d1\" tg-width=\"1260\" tg-height=\"840\"><span>Since 1979, the S&amp;P 500 has gained 10% or more 14 times during the first half of the year.</span></p><p><blockquote><p class=\"t-img-caption\"><span>自1979年以来，标普500上半年涨幅达到或超过10%已有14次。</span></p></blockquote></p><p> The S&amp;P 500 closed its second-best first half since the dot-com bubble. Don’t be surprised if the stock market keeps on rising.</p><p><blockquote>标普500的上半年表现是自互联网泡沫以来第二好的。如果股市继续上涨，不要感到惊讶。</blockquote></p><p> With June coming to an end, the S&amp;P 500 finished the first half of 2021 with a gain of 14.4%. Since 1998, only 2019’s 17.4% first-half surge has been larger.</p><p><blockquote>随着6月接近尾声，标普500以14.4%的涨幅结束了2021年上半年。自1998年以来，只有2019年上半年17.4%的增幅更大。</blockquote></p><p> The market got a boost from Covid-19 vaccinations, which have helped the U.S. economy reopen, while trillions of dollars of fiscal stimulus have helped shore up demand. The gains continued even as concerns about inflation have increased speculation that the Federal Reserve would be forced to take steps to slow the economy.</p><p><blockquote>Covid-19疫苗接种提振了市场，帮助美国经济重新开放，而数万亿美元的财政刺激措施帮助支撑了需求。尽管对通胀的担忧加剧了人们对美联储将被迫采取措施减缓经济增长的猜测，但涨幅仍在继续。</blockquote></p><p> The combination of big gains and a more hawkish Fed have raised concerns that the market has become too complacent. If inflation continues to run hot for long enough, the central bank could be forced to act more quickly than the market expects—and&nbsp;cause stocks to tumble. Others worry that&nbsp;U.S. economic growth could slow faster than investors anticipate, causing a pullback in the process.</p><p><blockquote>大幅上涨和美联储更加鹰派的结合引发了市场过于自满的担忧。如果通胀持续持续足够长的时间，央行可能会被迫以比市场预期更快的速度采取行动，并导致股市暴跌。其他人担心美国。经济增长放缓的速度可能快于投资者的预期，导致经济增长放缓。</blockquote></p><p> For those who take that view, there is no better time to back away from the stock market than the present. History suggests otherwise.</p><p><blockquote>对于持这种观点的人来说，没有比现在更好的退出股市的时机了。历史表明并非如此。</blockquote></p><p> Since 1979, the S&amp;P 500 has gained 10% or more 14 times during the first half of the year, and the index has gone on to average a 6.3% gain over the second half of the year. What’s more, the index finished the second half of the year higher In 11 of those instances, or 79% of the time.</p><p><blockquote>自1979年以来，标普500上半年涨幅达到或超过10%的有14次，下半年该指数平均涨幅为6.3%。更重要的是，该指数在下半年有11次（即79%的时间）走高。</blockquote></p><p> Even the losses, when they occurred, weren’t all that bad. The S&amp;P 500 dropped 1.9% in the second half of 1983 and 3.5% during the last six months of 1986.</p><p><blockquote>即使是损失，当它们发生时，也没有那么糟糕。标普500在1983年下半年下降了1.9%，在1986年最后六个月下降了3.5%。</blockquote></p><p> The one exception was the last six months of 1987 when the index fell 19% during the second half of the year. That period included Black Monday, when the S&amp;P 500 dropped 20% in one day, still a record loss. While selling linked to so-called&nbsp;portfolio insurance&nbsp;was ultimately blamed for the size and speed of the loss, the second half of 1987 was&nbsp;a period of rising bond yields and high stock-market valuations, just like the first half of 2021.</p><p><blockquote>一个例外是1987年的最后六个月，该指数在下半年下跌了19%。那段时间包括黑色星期一，当时标普500在一天内下跌了20%，仍然是创纪录的跌幅。虽然与所谓投资组合保险相关的抛售最终被归咎于损失的规模和速度，但1987年下半年是债券收益率上升和股市估值高的时期，就像2021年上半年一样。</blockquote></p><p> Still, the market has been acting like it wants to go higher, not lower. Pullbacks, a normal event in the midst of bull runs, have been mild in 2021, with the largest drops being less than 4%. “What the [S&amp;P 500] has done throughout 2021 is pick itself up when and where it has needed to, maintaining an uptrend all along,” writes Frank&nbsp;Cappelleri, chief market technician at Instinet.</p><p><blockquote>尽管如此，市场一直表现得想要走高，而不是走低。回调是牛市中的正常事件，在2021年表现温和，最大跌幅不到4%。Instinet首席市场技术员Frank Cappelleri写道：“[标普500]在2021年所做的就是在需要的时间和地点回升，始终保持上升趋势。”</blockquote></p><p> That 6.3% average second-half rise would push the S&amp;P 500’s full-year gain to around 23%. That would represent a “textbook [market] recovery” from a recession, says Fundstrat’s Tom Lee.</p><p><blockquote>下半年6.3%的平均涨幅将使标普500的全年涨幅达到23%左右。Fundstrat的汤姆·李(Tom Lee)表示，这将代表着从衰退中“教科书式的[市场]复苏”。</blockquote></p><p> For now, at least, the path of least resistance is higher.</p><p><blockquote>至少就目前而言，阻力最小的路径更高。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/3cb229b2e05d59b9c126d464a7d771bb\" tg-width=\"958\" tg-height=\"647\"></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/stock-market-futures-crash-gains-51625071996?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/stock-market-futures-crash-gains-51625071996?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106223449","content_text":"Since 1979, the S&P 500 has gained 10% or more 14 times during the first half of the year.\nThe S&P 500 closed its second-best first half since the dot-com bubble. Don’t be surprised if the stock market keeps on rising.\nWith June coming to an end, the S&P 500 finished the first half of 2021 with a gain of 14.4%. Since 1998, only 2019’s 17.4% first-half surge has been larger.\nThe market got a boost from Covid-19 vaccinations, which have helped the U.S. economy reopen, while trillions of dollars of fiscal stimulus have helped shore up demand. The gains continued even as concerns about inflation have increased speculation that the Federal Reserve would be forced to take steps to slow the economy.\nThe combination of big gains and a more hawkish Fed have raised concerns that the market has become too complacent. If inflation continues to run hot for long enough, the central bank could be forced to act more quickly than the market expects—and cause stocks to tumble. Others worry that U.S. economic growth could slow faster than investors anticipate, causing a pullback in the process.\nFor those who take that view, there is no better time to back away from the stock market than the present. History suggests otherwise.\nSince 1979, the S&P 500 has gained 10% or more 14 times during the first half of the year, and the index has gone on to average a 6.3% gain over the second half of the year. What’s more, the index finished the second half of the year higher In 11 of those instances, or 79% of the time.\nEven the losses, when they occurred, weren’t all that bad. The S&P 500 dropped 1.9% in the second half of 1983 and 3.5% during the last six months of 1986.\nThe one exception was the last six months of 1987 when the index fell 19% during the second half of the year. That period included Black Monday, when the S&P 500 dropped 20% in one day, still a record loss. While selling linked to so-called portfolio insurance was ultimately blamed for the size and speed of the loss, the second half of 1987 was a period of rising bond yields and high stock-market valuations, just like the first half of 2021.\nStill, the market has been acting like it wants to go higher, not lower. Pullbacks, a normal event in the midst of bull runs, have been mild in 2021, with the largest drops being less than 4%. “What the [S&P 500] has done throughout 2021 is pick itself up when and where it has needed to, maintaining an uptrend all along,” writes Frank Cappelleri, chief market technician at Instinet.\nThat 6.3% average second-half rise would push the S&P 500’s full-year gain to around 23%. That would represent a “textbook [market] recovery” from a recession, says Fundstrat’s Tom Lee.\nFor now, at least, the path of least resistance is higher.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":1536,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153855011,"gmtCreate":1625018679233,"gmtModify":1631890700052,"author":{"id":"3576125105535390","authorId":"3576125105535390","name":"Riyasaan","avatar":"https://static.tigerbbs.com/853ccf8f0efed6f3b600123ec0b321c3","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576125105535390","idStr":"3576125105535390"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/153855011","repostId":"1130740745","repostType":4,"repost":{"id":"1130740745","kind":"news","pubTimestamp":1625017527,"share":"https://www.laohu8.com/m/news/1130740745?lang=zh_CN&edition=full","pubTime":"2021-06-30 09:45","market":"us","language":"en","title":"Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1130740745","media":"AlphaStreet","summary":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to ","content":"<p>  The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.  The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.</p><p><blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote></p><p> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbol<b><i>AVTE</i></b>. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.</p><p><blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为<b><i>AVTE</i></b>.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote></p><p> <b>Cardiopulmonary Research</b></p><p><blockquote><b>心肺研究</b></blockquote></p><p> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.<b>The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.</b></p><p><blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。<b>这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</b></blockquote></p><p> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,<i>AV-101</i>, is an inhaler based on tyrosine kinase inhibitor<i>imatinib</i>. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.</p><p><blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，<i>AV-101</i>，是一种基于酪氨酸激酶抑制剂的吸入剂<i>伊马替尼</i>PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>New-Gen Drug for PAH</b></p><p><blockquote><b>治疗PAH的新一代药物</b></blockquote></p><p> <b>Early-stage clinical trials have indicated that</b><b><i>AV-101</i></b><b>is effective in treating patients suffering from PAH by acting directly on the cause of the disease.</b>In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.</p><p><blockquote><b>早期临床试验表明，</b><b><i>AV-101</i></b><b>通过直接作用于疾病的病因，可有效治疗患有PAH的患者。</b>在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote></p><p> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development of<i>AV-101</i>and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.</p><p><blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发<i>AV-101</i>并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote></p><p> <b>Risks</b></p><p><blockquote><b>风险</b></blockquote></p><p> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.<b>Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely on</b><b><i>AV-101</i></b><b>to become profitable.</b>Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.</p><p><blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。<b>长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于</b><b><i>AV-101</i></b><b>变得有利可图。</b>此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote></p><p> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.</p><p><blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote></p><p></p>","source":"lsy1609745492275","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">AlphaStreet</strong><span class=\"h-time small\">2021-06-30 09:45</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.  The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.</p><p><blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote></p><p> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbol<b><i>AVTE</i></b>. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.</p><p><blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为<b><i>AVTE</i></b>.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote></p><p> <b>Cardiopulmonary Research</b></p><p><blockquote><b>心肺研究</b></blockquote></p><p> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.<b>The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.</b></p><p><blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。<b>这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</b></blockquote></p><p> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,<i>AV-101</i>, is an inhaler based on tyrosine kinase inhibitor<i>imatinib</i>. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.</p><p><blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，<i>AV-101</i>，是一种基于酪氨酸激酶抑制剂的吸入剂<i>伊马替尼</i>PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>New-Gen Drug for PAH</b></p><p><blockquote><b>治疗PAH的新一代药物</b></blockquote></p><p> <b>Early-stage clinical trials have indicated that</b><b><i>AV-101</i></b><b>is effective in treating patients suffering from PAH by acting directly on the cause of the disease.</b>In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.</p><p><blockquote><b>早期临床试验表明，</b><b><i>AV-101</i></b><b>通过直接作用于疾病的病因，可有效治疗患有PAH的患者。</b>在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote></p><p> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development of<i>AV-101</i>and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.</p><p><blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发<i>AV-101</i>并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote></p><p> <b>Risks</b></p><p><blockquote><b>风险</b></blockquote></p><p> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.<b>Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely on</b><b><i>AV-101</i></b><b>to become profitable.</b>Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.</p><p><blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。<b>长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于</b><b><i>AV-101</i></b><b>变得有利可图。</b>此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote></p><p> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.</p><p><blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/\">AlphaStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130740745","content_text":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n\nThe IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.\nIn a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.\nCardiopulmonary Research\nThe Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.\nThe company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.\n\nNew-Gen Drug for PAH\nEarly-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.\nProceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.\nRisks\nIt goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.\nBeingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.","news_type":1,"symbols_score_info":{"AVTE":0.9}},"isVote":1,"tweetType":1,"viewCount":2637,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120581590,"gmtCreate":1624327824010,"gmtModify":1631884627215,"author":{"id":"3576125105535390","authorId":"3576125105535390","name":"Riyasaan","avatar":"https://static.tigerbbs.com/853ccf8f0efed6f3b600123ec0b321c3","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576125105535390","idStr":"3576125105535390"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CRM\">$Salesforce.com(CRM)$</a>Holding.&nbsp;","listText":"<a href=\"https://laohu8.com/S/CRM\">$Salesforce.com(CRM)$</a>Holding.&nbsp;","text":"$Salesforce.com(CRM)$Holding.","images":[{"img":"https://static.tigerbbs.com/b605df5482e37884bec85d00d0c4b741","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/120581590","isVote":1,"tweetType":1,"viewCount":1551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":165113407,"gmtCreate":1624105109609,"gmtModify":1631890700054,"author":{"id":"3576125105535390","authorId":"3576125105535390","name":"Riyasaan","avatar":"https://static.tigerbbs.com/853ccf8f0efed6f3b600123ec0b321c3","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576125105535390","idStr":"3576125105535390"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TAL\">$TAL Education Group(TAL)$</a>Pls go up","listText":"<a href=\"https://laohu8.com/S/TAL\">$TAL Education Group(TAL)$</a>Pls go up","text":"$TAL Education Group(TAL)$Pls go up","images":[{"img":"https://static.tigerbbs.com/25963faa498e0101951ac0969db39555","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/165113407","isVote":1,"tweetType":1,"viewCount":1360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":166226932,"gmtCreate":1624013359426,"gmtModify":1631890700056,"author":{"id":"3576125105535390","authorId":"3576125105535390","name":"Riyasaan","avatar":"https://static.tigerbbs.com/853ccf8f0efed6f3b600123ec0b321c3","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576125105535390","idStr":"3576125105535390"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166226932","repostId":"2144742013","repostType":4,"isVote":1,"tweetType":1,"viewCount":1928,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166228897,"gmtCreate":1624013328919,"gmtModify":1631890700058,"author":{"id":"3576125105535390","authorId":"3576125105535390","name":"Riyasaan","avatar":"https://static.tigerbbs.com/853ccf8f0efed6f3b600123ec0b321c3","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576125105535390","idStr":"3576125105535390"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166228897","repostId":"2144491778","repostType":4,"isVote":1,"tweetType":1,"viewCount":1519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166229336,"gmtCreate":1624013149525,"gmtModify":1631884627223,"author":{"id":"3576125105535390","authorId":"3576125105535390","name":"Riyasaan","avatar":"https://static.tigerbbs.com/853ccf8f0efed6f3b600123ec0b321c3","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576125105535390","idStr":"3576125105535390"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CRM\">$Salesforce.com(CRM)$</a>Keeping strong","listText":"<a href=\"https://laohu8.com/S/CRM\">$Salesforce.com(CRM)$</a>Keeping strong","text":"$Salesforce.com(CRM)$Keeping strong","images":[{"img":"https://static.tigerbbs.com/3dbf239f09d4ea2e7000fd934b87245b","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/166229336","isVote":1,"tweetType":1,"viewCount":1173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":169055613,"gmtCreate":1623810149632,"gmtModify":1631884627262,"author":{"id":"3576125105535390","authorId":"3576125105535390","name":"Riyasaan","avatar":"https://static.tigerbbs.com/853ccf8f0efed6f3b600123ec0b321c3","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576125105535390","idStr":"3576125105535390"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CRM\">$Salesforce.com(CRM)$</a>Strong","listText":"<a href=\"https://laohu8.com/S/CRM\">$Salesforce.com(CRM)$</a>Strong","text":"$Salesforce.com(CRM)$Strong","images":[{"img":"https://static.tigerbbs.com/79efe602901f95957724673c0697ada7","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/169055613","isVote":1,"tweetType":1,"viewCount":1642,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":169051322,"gmtCreate":1623810006166,"gmtModify":1631890700063,"author":{"id":"3576125105535390","authorId":"3576125105535390","name":"Riyasaan","avatar":"https://static.tigerbbs.com/853ccf8f0efed6f3b600123ec0b321c3","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576125105535390","idStr":"3576125105535390"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TAL\">$TAL Education Group(TAL)$</a>can we expect10% up move from here","listText":"<a href=\"https://laohu8.com/S/TAL\">$TAL Education Group(TAL)$</a>can we expect10% up move from here","text":"$TAL Education Group(TAL)$can we expect10% up move from here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169051322","isVote":1,"tweetType":1,"viewCount":1418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}